Category Archives: Ventricular Remodeling

DelveInsights Heart Failure (HF) with Reduced Ejection Fraction (HFrEF) Market Insights, Epidemiology, and Market Forecast 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Heart Failure with Reduced Ejection Fraction market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan). Continue reading →

Heart failure (HF) is a complex clinical condition that results from any structural and functional cardiac disease that leads to an inability to fill the heart chamber or propel the blood forward [1].Congenital heart disease (CHD) is the most important reason for congestive HF (CHF) in children [1]. Depending on the etiology, drug therapy is used to either shorten the time awaiting necessary curative surgery or manage HF on a long-term basis Continue reading →

The etiology of IPAH is unknown, yet the disease places a great physical, mental, and economic burden on patients. Existing studies have identified a proportion of new biomarkers able to facilitate the diagnosis of IPAH. Continue reading →

A ventricular aneurysm is a dreaded myocardial infarction complication that develops in post-myocardial infarction's remodeling phase. There can be true aneurysms and false aneurysms; the latter constitute only of pericardial layer; it lacks myocardial and epicardial elements [1]. Continue reading →

Congestive heart failure (CHF) is a cardiac dysfunction syndrome characterized by a reduced left ventricular ejection fraction (LVEF) associated with water and sodium retention. Muscle weakness and early fatigue are the two primary symptoms of CHF patients. The prevalence of CHF is approximately 1% to 3% in western societies. Continue reading →

HANOVER, Germany--(BUSINESS WIRE)--Cardior Pharmaceuticals, a clinical-stage biotech company developing non-coding RNA (ncRNA)-based therapeutics for patients with cardiac diseases, today announced the CE marking of its PCR kit which measures circulating microRNA-132 (miR-132) levels in the blood of patients receiving the companys lead candidate CDR132L, an oligonucleotide-based miR-132 inhibitor. The company is currently conducting its Phase 2 clinical study, HF-REVERT (NCT05350969), to evaluate the safety and efficacy of CDR132L in patients with heart failure and reduced left ventricular ejection fraction (LVEF) after a myocardial infarction. By using the CardiorHealth miR-132 PCR kit, Cardior ensures consistent measurement of miR-132 levels following CDR132L treatment across all clinical trial centers as an indicator of the target engagement and the compounds mechanism of action. Continue reading →

Virani SS, Alonso A, Benjamin EJ, Bittencourt MS, Callaway CW, Carson AP, et al. Heart disease and stroke statistics-2020 update: a report from the American Heart Association. Circulation Continue reading →

Introduction Hypertension is a major risk factor of cardiovascular morbidity and mortality in China and worldwide.13 According to the China Hypertension Survey,4 the number of adults with hypertension is nearly 245 million. Continue reading →

NEW YORK, May 03, 2022 (GLOBE NEWSWIRE) -- LEXEO Therapeutics (LEXEO), a clinical-stage gene therapy company advancing a pipeline of adeno-associated virus (AAV)-based gene therapy candidates for genetically defined cardiovascular and central nervous system (CNS) diseases, today announced that new preclinical data supporting its plakophilin-2 (PKP2) arrhythmogenic right ventricular cardiomyopathy (ARVC) program, Friedreichs ataxia (FA) cardiomyopathy program, and second-generation APOE4 Alzheimers disease program will be presented at the 25th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT), which is being held live in Washington, D.C. and virtually from May 16-19, 2022. Continue reading →

Medical researchers have stayed busy in recent years working to develop new interventional heart failure treatments that offer more relief than guideline-directed medical therapy (GDMT) without requiring a left ventricular assist device (LVAD) or heart transplant. The interventional cardiologists at Cleveland Clinics Sydell and Arnold Miller Family Heart, Vascular and Thoracic Institute, for instance, are involved in multiple clinical trials exploring these promising therapies Continue reading →